GM-2505 – Talk Bio

Actionable Insights Powered by AI

AbbVie Buys Gilgamesh’s Psychedelic Drug Bretisilocin for $1.2B

24 hours ago talkbio0Tagged AbbVie, Acquisition, bretisilocin, Dosage Forms, Gilgamesh, GM-2505, Hallucinogens, mental health, Neuroscience discipline

AbbVie; Gilgamesh Pharmaceuticals; psychedelic drug; bretisilocin; GM-2505; major depressive disorder; acquisition; mental health; neuroscience; pharmaceutical deal